Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

141.29 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Looking At AbbVie's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades. 
Via Benzinga
AbbVie, Sosei Build In 2020 Pact With New Neurological Disease-Focused Agreement
 
Via Benzinga
6 Analysts Have This to Say About AbbVie
AbbVie (NYSE:ABBV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
What Are Whales Doing With AbbVie
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades. 
Via Benzinga
This Analyst Cuts I-Mab's Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.  
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
AbbVie's quarterly results were roughly in line with Wall Street's expectations, but ABBV stock still slipped in early trading. 
Via InvestorPlace
AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook
Humira sales are still growing, though more slowly in previous years. 
Via Investor's Business Daily
AbbVie's Q2 Sales Marginally Shy Of Wall Street Estimates, Confirms Annual Profit Outlook
 
Via Benzinga
AbbVie Calls Off Early-Stage Trial For I-Mab's CD47-Targeted Blood Cancer Candidate
 
Via Benzinga
180 Life Sciences: Why Investors Should Take Notice
180 Life Sciences is an under the radar stock worthy of a closer look. We sat down with CEO Dr. James Woody to dig deeper into ATNF to learn if the stock merits being added to your portfolio. 
Via Talk Markets
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years
  AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 3.64% on an annualized basis producing an average annual return of 15.04%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
7 Blue-Chip Stocks That Will Survive 2022
These are among the best blue-chip stocks to buy now. Here's why ABBV, BDX, CI, DD, MMM, JPM, and PFE can make great investments. 
Via InvestorPlace
The 3 Best Vanguard Funds to Buy in August
VCR, VHT and VYM are among the best Vanguard funds to buy now. Here is why they will make great investments in the coming months. 
Via InvestorPlace
The 7 Most Undervalued Value Stocks to Buy Now
Add these undervalued value stocks to your buy list. They still remain cheap even as value stocks have come into favor this year. 
Via InvestorPlace
7 Cheap Biotech Stocks to Buy Now
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector. 
Via InvestorPlace
Recession Investing: 5 High Yield Dividend Stocks For A Downturn
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their... 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Target And Chevron Get CNBC Fast Money Mentions With Joe Terranova Rebalancing His ETF
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
Peering Into AbbVie's Recent Short Interest
AbbVie's (NYSE:ABBV) short percent of float has fallen 18.37% since its last report. The company recently reported that it has 14.03 million shares sold short, which is 0.8% of... 
Via Benzinga
Best Stocks To Hold For The Recession
During a recession, it is not time to change your entire investment plan. But if you need to rebalance, sell some losers, or if you have money to invest, here are some good recession performers. 
Via Talk Markets
Recap Of Friday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
The major indexes made big moves amid key earnings and another big Fed rate hike. 
Via Investor's Business Daily
Recap: AbbVie Q2 Earnings
  AbbVie (NYSE:ABBV) reported its Q2 earnings results on Friday, July 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement. Earnings AbbVie beat estimated earnings by 1.2%,... 
Via Benzinga
Preview: AbbVie's Earnings
AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-07-29. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will report an... 
Via Benzinga
Earnings Scheduled For July 29, 2022
Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.